On Invalid Date, Neoleukin Therapeutics (NASDAQ: NLTX) reported Q4 2022 earnings per share (EPS) of -$0.24, up 11.11% year over year. Total Neoleukin Therapeutics earnings for the quarter were -$13.45 million. In the same quarter last year, Neoleukin Therapeutics's earnings per share (EPS) was -$0.27.
As of Q1 2023, Neoleukin Therapeutics's earnings has grown year over year. Neoleukin Therapeutics's earnings in the past year totalled -$59.28 million.
What is NLTX's earnings date?
Neoleukin Therapeutics's earnings date is Invalid Date. Add NLTX to your watchlist to be reminded of NLTX's next earnings announcement.
What was NLTX's revenue last quarter?
On Invalid Date, Neoleukin Therapeutics (NASDAQ: NLTX) reported Q4 2022 revenue of $0.00 up N/A year over year. In the same quarter last year, Neoleukin Therapeutics's revenue was $0.00.
What was NLTX's revenue growth in the past year?
As of Q1 2023, Neoleukin Therapeutics's revenue has grown null year over year. Neoleukin Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.